Phase 1 study data for EP0031/A400, presented at ASCO 2024 Download larger version About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding [...]
Ellipses’ next generation selective RET inhibitor EP0031/A400 cleared to start Phase 2 clinical development Drug has successfully completed US Food and Drug Administration’s End of Phase 1 data review. Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today the [...]
Dr Elena Garralda Cabanas shares her thoughts on the EP0031 phase 1 study data for patients with advanced RET-altered tumors. In this video, Dr. Elena Garralda Cabanas, Co-director of the Clinical Research Program at VHIO, discusses her enthusiasm for the data presented in a phase 1 study for patients with advanced RET-altered tumors. View all [...]
Dr Matthew Krebs on the potential of EP0031 in transforming the landscape of RET-altered cancer In this video, Dr. Matthew Krebs, Clinical Senior Lecturer in Experimental Cancer Medicine at the University of Manchester, shares his thoughts on the potential of EP0031 in transforming the landscape of RET-altered cancer treatment. With preliminary data showcasing encouraging efficacy [...]
Ellipses Pharma features in the Guardian Innovations In Oncology and Imaging Series As part of The Guardian's Innovations in Oncology and Imaging series, our Chairman and Co-Founder Professor Sir Chris Evans OBE, and our CMO Professor Tobi Arkenau explain how our unique and disruptive drug development model is accelerating the development of potential new cancer [...]
Unlocking the Potential of RET-Targeted Cancer Therapies Simple Summary: Since the discovery of the RET gene in the early 1980s, multiple treatments have been developed that can inhibit abnormal RET signaling. The first treatments were repurposed multikinase inhibitors, however, their low selectivity for RET led to unacceptable off-target toxicities and sub-optimal exposure in patients. More [...]
Ellipses EP0031 granted Orphan Drug Designation from the US Food and Drug Administration EP0031/A400, a next generation selective RET inhibitor (SRI), is currently being investigated as a treatment option for patients with RET altered tumours Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug [...]
A Phase 1 Study of KL590586 (A400/EP0031) - A next-generation selective RET inhibitor in patients with RET-altered solid tumours Download PDF About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to [...]
